Sylvie M Guichard

FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer

B. Graves, A. Chicas, K. Wood, 2023, Targeted Oncology.

FT-4202, an oral PKR activator, has potent antisickling effects and improves RBC survival and Hb levels in SCA mice.

P. Malik, A. Drake, A. Shrestha, 2021, Blood advances.

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.

J. Nissink, A. Lau, P. Jewsbury, 2018, Journal of medicinal chemistry.

Etavopivat, a Pyruvate Kinase Activator in Red Blood Cells, for the Treatment of Sickle Cell Disease

E. Wilker, A. Drake, P. Schroeder, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.

A. Wei, S. de Botton, Sangmin Lee, 2022, The Lancet. Haematology.

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

M. Reimers, N. Shore, M. Gordon, 2021 .

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant gliomas: Safety and efficacy as single agent and in combination with azacitidine.

H. Colman, M. Milhem, M. Rosenthal, 2020 .

A phase Ib/II study of olutasidenib in patients with relapsed/refractory IDH1 mutant solid tumors: Safety and efficacy as single agent.

Robin L. Jones, J. Blay, A. Italiano, 2020 .

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

J. Cortes, A. Wei, Sangmin Lee, 2019, Blood.